(Q39383689)

11 September 2017

title

Therapeutic potential of MEK inhibition in acute myelogenous leukemia: rationale for "vertical" and "lateral" combination strategies (English)

1 reference

11 September 2017

1 reference

16

Robin Foà

1 reference

11 September 2017

13

Marina Konopleva

1 reference

11 September 2017

17

Michael Andreeff

1 reference

11 September 2017

19

Agostino Tafuri

1 reference

11 September 2017

18

James A McCubrey

1 reference

11 September 2017

11

Twee Tsao

1 reference

11 September 2017

20

Michele Milella

1 reference

11 September 2017

15

Francesco Cognetti

1 reference

11 September 2017

4

Ludovica Ciuffreda

1 reference

11 September 2017

Maria Rosaria Ricciardi

1

object named as

Maria Rosaria Ricciardi

1 reference

11 September 2017

Maria Teresa Petrucci

5

object named as

Maria Teresa Petrucci

1 reference

11 September 2017

10

Linda S Steelman

1 reference

11 September 2017

author name string

Maria Cristina Scerpa

2

1 reference

11 September 2017

Paola Bergamo

3

1 reference

11 September 2017

Sabina Chiaretti

6

1 reference

11 September 2017

Simona Tavolaro

7

1 reference

11 September 2017

Maria Grazia Mascolo

8

1 reference

11 September 2017

Stephen L Abrams

9

1 reference

11 September 2017

Antonio Marchetti

12

1 reference

11 September 2017

Donatella Del Bufalo

14

1 reference

11 September 2017

publication date

8 March 2012

1 reference

Journal of Molecular Medicine

11 September 2017

published in

1 reference

11 September 2017

volume

90

1 reference

11 September 2017

issue

10

1 reference

11 September 2017

page(s)

1133-1144

1 reference

https://scigraph.springernature.com/pub.10.1007/s00109-012-0886-z

11 September 2017

exact match

0 references

cites work

Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

Targeting the mitogen-activated protein kinase cascade to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

ERK1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

Beyond single pathway inhibition: MEK inhibitors as a platform for the development of pharmacological combinations with synergistic anti-leukemic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

Response and resistance to MEK inhibition in leukaemias initiated by hyperactive Ras

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

Synergistic induction of apoptosis by simultaneous disruption of the Bcl-2 and MEK/MAPK pathways in acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

MEK blockade converts AML differentiating response to retinoids into extensive apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

MEK1 inhibition sensitizes primary acute myelogenous leukemia to arsenic trioxide-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

Targeting MEK/MAPK signal transduction module potentiates ATO-induced apoptosis in multiple myeloma cells through multiple signaling pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

Targeting survival cascades induced by activation of Ras/Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways for effective leukemia therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

A MEK inhibitor abrogates myeloproliferative disease in Kras mutant mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

A conditionally-active form of MEK1 results in autocrine tranformation of human and mouse hematopoietic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

ERK implication in cell cycle regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

Growth-inhibitory and antiangiogenic activity of the MEK inhibitor PD0325901 in malignant melanoma with or without BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

Clinical experience of MEK inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

Signaling dynamics of the KSR1 scaffold complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

Induction of Bim expression contributes to the antitumor synergy between sorafenib and mitogen-activated protein kinase/extracellular signal-regulated kinase kinase inhibitor CI-1040 in hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00109-012-0886-Z

Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22399013

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00109-012-0886-Z

1 reference

11 September 2017

1 reference